An update of the leukotriene modulators for the treatment of asthma

Bibliography

• NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM: Expert Panel Report 2: guidelines for the diagnosis and management of asthma. NIH Publication No. 97–4051. Bethesda (1997).
   Google Scholar
• SAMUELSSON B, DAHLEN SE, LINDGREN JA, ROUZER CA, SERHAN CN: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. (1987) 237:1171–1176.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST, BRADDING P, SAMPSON AP: Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. I Allergy Clin. Immunol (1996) 98:1–13.
   PubMed Web of Science ®Google Scholar
• •A complete review about the antileukotriene drugs.
   Google Scholar
• COLEMAN RA, EGLEN RM, JONES RL et al.: Prostanoid and leukotrienes receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prost. Thromb. Leak°. Res. (1995) 23:283–285.
   PubMedGoogle Scholar
• FORD-HUTCHINSON AW, BRAY MA, DOIG MV, SHIPLEY ME, SMITH MJ: Leukotriene B4, a potent chemokinetic and aggregating substance released from PMN leukocytes. Nature. (1980) 286:264–265.
   PubMed Web of Science ®Google Scholar
• FORD-HUTCHINSON AW: Leukotriene B4 in inflammation. Crit. Rev Immunol (1990) 10:1–12.
   PubMed Web of Science ®Google Scholar
• PIPER PJ: Formation and actions of leukotrienes. Physiol Rev (1984) 64:744–761.
   PubMed Web of Science ®Google Scholar
• LYNCH KR, O'NEILL GP, LIU Q et al.: Characterization of the human cysteinyl leukotriene Cys-LT1 receptor. Nature (1999) 399:789–793.
   Google Scholar
• RICCIONI G, SANTILLI F, D'ORAZIO N et al.: The role of antileukotrienes in the treatment of asthma. Int. .1 Immunopathol Pharmacol (2002) 15:171–182.
   Google Scholar
• ••A critical review of antileukotrienes in thetreatment of bronchial asthma.
   Google Scholar
• GLOBAL INITIATIVE FOR ASTHMA:Pocket guide for asthma management and prevention. NIH publicationNo.96-3659B. Bethesda (1998).
   Google Scholar
• BRITISH ASTHMA GUIDELINES COORDINATING COMMITTEE: British guidelines on asthma management: 1995 review and position statement. Thorax. (1997) 52:S1–S24.
   Google Scholar
• CLARK N, JONES P, KELLER S, VERIVIEIRE P: Patient factor and compliance with asthma therapy. Pediatr. Pulmonol (2000) 29:46–61.
   PubMedGoogle Scholar
• KELLOWAY JS, WYATT RA, ADLIS SK: Comparison of patient's compliance with prescribed oral and inhaled asthma medication. Arch. Intern. Med. (1994) 154:1349–1352.
   PubMed Web of Science ®Google Scholar
• SPECTOR S: Noncompliance with asthma therapy - are there solutions? j Asthma. (2000) 37:381–388.
   Google Scholar
• BARNES PJ, PEDERSEN S, BUSSE W: Efficacy and safety of inhaled corticosteroids: new development. Am. Respir. Crit. Care. Med. (1998) 157:S1–S53.
   PubMed Web of Science ®Google Scholar
• DWORSKI R, FITZGERALD GA, OATES JA, SHELLER JR: Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Respir. Grit. Care. Med. (1994) 149:953–959.
   PubMed Web of Science ®Google Scholar
• HOOD PP, COTTER TP, COSTELLO JF, SAMPSON AP: Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients. Thorax (1999) 54:1075–1082.
   PubMed Web of Science ®Google Scholar
• BOOTH HI, RICHMOND I,WARD C, GARDINER PV, HARKAWAT R, WALTERS EH: Effect of high dose of inhaled fluticasone propionate on airway inflammation in asthma. Clin. Endocr. Metab. (1995) 80:1243–1246.
   Google Scholar
• BARNES PJ: Efficacy of inhaled corticosteroids in asthma. Allergy Clin. Immunol (1998) 102:531–538.
   Google Scholar
• EL-RADHI AS, HOGG CL, BUNGRE JK, BUSH A, CORRIGAN CJ: Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch. Dis. Child. (2000) 83:158–162.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Inhaled glucocorticoids for asthma. N Engl. I Med. (1995) 332:868–875.
   PubMed Web of Science ®Google Scholar
• •A complete review about the glucocorticosteroid therapy in asthma.
   Google Scholar
• VATHEEN AS, KNOX AJ, WISIEWSKI A, TATTERSFIELD AE: Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am. Rev Respir. Dis. (1991) 143:1317–1321.
   PubMed Web of Science ®Google Scholar
• BELL EH, TIMMERS MC, HERMANS J,DIJKMAN H, STERK PJ: The long-term effect of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am. Rev Respir. Dis. (1990) 141:21–28.
   PubMed Web of Science ®Google Scholar
• JUNIPER EP, KLINE PA, VANZIELEGHEM MA, RAMSDALE EH, O'BYRNE PM, HARGREAVE PK: Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Respir. Rev Dis. (1990) 142:832–836.
   PubMed Web of Science ®Google Scholar
• DJUKANOVIC R, LAI CK, WILSON JWet al.: Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev Respir. Dis. (1992) 256:669–674.
   Google Scholar
• BANOV CH, HOWLAND WC, LUMRY WR: Once-daily budesonide via Turbohaler improves symptoms in adults with persistent asthma. Ann. Allergy Asthma Immunol (2001) 86:627–632.
   PubMed Web of Science ®Google Scholar
• BANOV C, HOWLAND WC, LUMRY WR, PARASURAMAN B, URNYAK T, LILJAS B: Budesonide turbohaler delivered once daily improved health-related quality of life in adult patients with non-steroid-dependent asthma. All. Asthma. Proc. (2003) 24:129–136.
   PubMed Web of Science ®Google Scholar
• NIKOLAIZIK WH, MARCHANT JL, PREECE MA, WARNER JO: Endocrine and lung function in asthmatic children on inhaled corticosteroid. Am. .1 Respir. Crit. Care. Med. (1994) 150:624–629.
   PubMed Web of Science ®Google Scholar
• WONG CA, WALSH LJ, SMITH CJ et al.: Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet. (2000) 355:1399–1403.
   PubMed Web of Science ®Google Scholar
• LEONE FT, FISH JE, SZEFLER SJ, WEST SL: Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest (2003) 124:2329–2340.
   PubMed Web of Science ®Google Scholar
• LIPWORTH PJ, WILSON AM: Dose response to inhaled corticosteroids: benefits and risks. Sem. Resp. Critical. Care. Med. (1998) 19:625–646.
   Web of Science ®Google Scholar
• DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying leukotriene pathway. N Engl. I Med. (1999) 340:197–206.
   PubMed Web of Science ®Google Scholar
• •• A good systematic evaluation of the effect of glucocoricoids in the therapy of bronchial asthma.
   Google Scholar
• WENZEL SE: Antileukotriene drugs in themanagement of asthma. JAMA. (1998) 280:2068–2069.
   PubMed Web of Science ®Google Scholar
• SPECTOR SL: Management of asthma with zafirlukast. Clinical experience and tolerability profile. Drugs (1996) 54:369–384.
   Google Scholar
• MARKHAM A, FAULDS D: Montelukast. Drugs (1998) 56:251–256.
   PubMed Web of Science ®Google Scholar
• SMITH LJ: A risk-benefit assessment of antileukotrienes in asthma. Drug Sal (1998) 19:205–218.
   PubMed Web of Science ®Google Scholar
• •A review demonstrating the risk benefit of therapy with antileukotrienes.
   Google Scholar
• KNORR B, MATZ J, BERNSTEIN JA: Montelukast for chronic asthma in 6- to 14-year old children. A randomized, double-blind trial. JAMA (1998) 279:1181–1186.
   Google Scholar
• CALHOUN WJ, LAVINS BJ, MINKWITZ MC, EVANS R, GEICH GI, COHN J: Effect of zafirlukast (Accolate) on cellular mediators of inflammation: brocnhoalveolar lavage fluid findings after segmental antigen challenge. Am. J. Respic Crit. Care. Med. (1998) 157:1381–1389.
   PubMed Web of Science ®Google Scholar
• BUSSE W, RAPHAEL GD, GALANT S et al.: Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized controlled trial. j Allergy Clin. Immunol (2001) 107:461–468.
   PubMed Web of Science ®Google Scholar
• RICCIONI G, BALLONE E, SENSI S et al.: Effectiveness of monteukast versus budesonide on quality of life and bronchial reactivity in subjects with mild-persistent asthma. Lit. I Immunopathol Pharmacol (2002) 15:149–155.
   PubMed Web of Science ®Google Scholar
• •A study about the improvement of Oa, with MON compared with budesonide.
   Google Scholar
• ROSENTHAL R, LAVINS BJ, HANBY LA: Effect of treatment with zafirlukast (Accolate) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma. J. Allergy Clin. Immunol (1997) 97:250–255.
   Google Scholar
• RICCIONI G, CASTRONUOVO M, DE BENEDICTIS M et al: Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma. hat. J. Immunopathol Pharmacol (2001) 14:87–92.
   PubMed Web of Science ®Google Scholar
• LEFF JA, BUSSE WW, PEARLMAN D,BRONSKY EA, KEMP J, HENDELES L: Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl. J. Med. (1998) 339:147–152.
   PubMed Web of Science ®Google Scholar
• REISS TF, HILL JB, HARMAN E et al: Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax (1997) 52:1030–1035.
   PubMed Web of Science ®Google Scholar
• MASTALERZ L, GAWLEWICZ-MROCZKA A, NIZANKOWSKA E, CMIEL A, SZCZEKLIK A: Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin. Exp. Allergy (2002) 32:1360–1365.
   PubMed Web of Science ®Google Scholar
• REISS TF, CHERVINSKY P, DOCKHORN RJ, SHINGO S, SEIDENBERG B, EDWARDS TB: Montelukast, a once-daily leukotriene-receptor antagonist, in the treatment of chronic asthma. Arch. Intern. Med. (1998) 158:1213–1220.
   PubMed Web of Science ®Google Scholar
• FISH JE, KEMP JP, LOCKEY RF, GLASS M, HANBY LA, BONUCCELLI CM: Zafirlukast for symptomatic mild-to moderate asthma: a 13-week multicenter study. The Zafirlukast Trialist Group. Clin. The]: (1997) 19:675–690.
   Google Scholar
• SUISSA S, DENNIS R, ERNST P, SHEEHY 0, WOOD-DAUPHINEE S: Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1997) 126:177–183.
   PubMed Web of Science ®Google Scholar
• PRICE DB, HERNANDEZ D, MAGYAR P et al.: Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax (2003) 58:211–216.
   Google Scholar
• ••Important recent randomised controlledtrial on the beneficial effects of montelukast compared with budesonide in the treatment of asthma.
   Google Scholar
• REISS TF, NGUYEN HH, BRATTON DL: Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to years. Pediatrics (2001) 108:E48.
   PubMedGoogle Scholar
• SINGULAIR TABLETS AND CHEWABLE TABLETS (montelukast sodium): Physicians' Desk Reference (53rd Edition) Medical Economics Co, MJ, USA (1999):1886–1889.
   Google Scholar
• SPECTOR SL AND ANTILEUKOTRIENE WORKING GROUP: Safety of antileukotriene agents in asthma management. Ann. All. Asthma. Immunol (2001) 86:18–23.
   PubMed Web of Science ®Google Scholar
• ••A general review that demostrates thesafety of the use of antileukotrine drugs.
   Google Scholar
• SINGULAIR: Manufacturer's prescribing information. Merck and Co, NJ, USA (1999).
   Google Scholar
• JONES TR, LABELLE M, BELLEY M et al. : Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol Pharmacol (1995) 73:191–195.
   PubMed Web of Science ®Google Scholar
• KANNIESS F, RICHTER K, JANICKI S, SCHLEISS MB, JORRES RA, MAGNUSSEN H: Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. Eur: Respic J. (2002) 20:1080–1087.
   PubMed Web of Science ®Google Scholar
• •An important study about the dose reduction of ICs with the introduction of MON.
   Google Scholar
• BISGAARD H, NIELSEN KG: Bronchoprotection from leukotriene receptor antagonist in asthmatic pre-school children. Am. J. Respir. Grit. Care. Med. (2000) 162:187–190.
   PubMed Web of Science ®Google Scholar
• MEYER KA, ARDUINO JM, SANTANELLO NC, KNORR BA, BISGAARD H: Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J. Allergy Clin. Immunol (2003) 111:757–762.
   PubMed Web of Science ®Google Scholar
• NOONAN MJ, CHERVINSKY P, BRANDONT M et al.: Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur: Respic J. (1998) 11:1232–1239.
   PubMed Web of Science ®Google Scholar
• MALMSTROM K, RODRIGUEZ-GOMEZ G, GUERRA J et al.: Oral montelukast, inhaled beclometasone, and placebo for chronic asthma. Ann. Intern. Med. (1999) 130:487–495.
   PubMed Web of Science ®Google Scholar
• ALTMAN LC, MUNK Z, SELTZER J et al.: A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J. Allergy Clin. Immunol (1998) 102:50–56.
   PubMed Web of Science ®Google Scholar
• LAVIOLETTE M, MALMSTROM K, LU S et al.: Montelukast added to inhaled beclometasone in treatment of asthma. Am. .1. Respir. Crit. Care. Med. (1999) 160:1862–1868.
   Google Scholar
• EDELMAN JM, TURPIN JA, BRONSKY EA et al.: Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann. Intern. Med. (2000) 132:97–104.
   PubMed Web of Science ®Google Scholar
• RODRIGO GJ, RODRIGO C: Intravenous montelukast in acute asthma. Am. .1. Respir. Grit. Care. Med. (2004) 169:130–131.
   PubMedGoogle Scholar
• •The first study with the use of intravenous MON.
   Google Scholar
• CAMARGO CA Jr, SMITHLINE HA, MALICE MP, GREEN SA, REISS TF: A randomized controlled trial of intravenous montelukast in acute asthma. Am. .1. Respir. Grit. Care. Med. (2003) 167:528–533.
   PubMed Web of Science ®Google Scholar
• BAUM D, CREER TL: Medication compliance in children with asthma. .1. Asthma. (1986) 23:49–59.
   PubMed Web of Science ®Google Scholar
• •An important review that explains the compliance of different drugs in asthma therapy.
   Google Scholar
• CREER TL: Medication compliance and childhood asthma. In: Developmental Aspects of Health Compliance Behavior NA Krasenger, L Epstein, SB Johnson, SJ Jaffe (Eds), Lawrence Erbaum Associates, Hillsdale, NJ, USA (1999):303–333.
   Google Scholar
• JONASSON G, CARLSEN KH, MOWINCKEL P: Asthma drug adherence in a long term clinical trial. Arch. Dis. Child. (2000) 83:330–333.
   PubMed Web of Science ®Google Scholar
• ACCOLATE: Manufacturer's prescribing information. Zeneca Pharmaceuticals, Carolina, Puerto Rico (1999).
   Google Scholar
• ADKINS JC, BROGDEN RN: Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. Drugs (1998) 55:121–144.
   Google Scholar
• SPECTOR SL, SMITH LJ, GLASS M: Effects of 6-weeks of therapy with oral doses of IC1,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am. I Respir. Grit. Care. Med. (1994) 150:618–623.
   PubMed Web of Science ®Google Scholar
• DUNN CJ, GOA KL: Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs (2001) 61:285–315.
   PubMed Web of Science ®Google Scholar
• NATHAN RA, BERNSTEIN JA, BIELORY L et al.: Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. I Allergy Clin. Immunol (1998) 102:935–942.
   PubMed Web of Science ®Google Scholar
• PEARLMAN DS, OSTROM NK, BRONSKY EA, BONUCCELLI CM, HANBY LA: The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. Pediam. (1998) 134:273–276.
   Google Scholar
• CROPP GJA: Third international pediatric consensus statement on the management of childhood asthma. Pediam Pulmonol (1998) 25:1–17.
   PubMed Web of Science ®Google Scholar
• KNORR B, FRANCHI LM, BISGAARD H et al: Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study. Chang. Gang. Med. J. (2003) 26:554–560.
   PubMedGoogle Scholar
• •An important randomised, controlled study about the therapy with ZAF and the dose reduction on corticosteroids.
   Google Scholar
• BRABSON JH, CLIFFORD D, KERWIN E et al.: Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. Am. I Med. (2002) 113:15–21.
   Web of Science ®Google Scholar
• •An important study comparing a low dose of fluticasone versus ZAF.
   Google Scholar
• LAKOMSKI PG, CHITRE M: Evaluation of the utilization patterns of leukotriene modifiers in a large managed care health plan. I Manag. Care Pharm. (2004) 10:115–121.
   PubMedGoogle Scholar
• ACCOLATE (zafirlukast tablets): Physicians' Desk Reference (53rd Edition). Medical Economics Co, Montvale, MJ, USA: (1999) 3402–3404.
   Google Scholar
• KEMP JP, KORENBLAT PE, SCHERGERJE, MINKWITZ M: Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. Fam. Pract. (1999) 48:425-432. ao. KEAM SJ, LYSENG-WILLIAMSON KA, GOA KL: Pranlukast: a review of its use in the management of asthma. Drugs (2003) 63:991–1019.
   Google Scholar
• HORIGUCHI T, KONDO R, MIYAZAKI J et al.: Clinical effects of long- term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma. Nihon Kokyuki Cakkai Zasshi (2003) 41:696–703.
   PubMedGoogle Scholar
• TOMARI S, SHIMODA T, KAWANO T et al.: Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann. Allergy Asthma Immunol (2001) 87:156–161.
   PubMed Web of Science ®Google Scholar
• OBASE Y, SHIMODA T, TOMARI S et al.: Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year follow-up study. Ann. Allergy Asthma Immunol (2001) 87:43–47.
   PubMed Web of Science ®Google Scholar
• Y00 SH, PARK SH, SONG JS et al: Representing Korea Pranlukast Study Group. Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. Respirology (2001) 6:15–21.
   Google Scholar
• YOSHIDA S, ISHIZAKI Y, SHOJI T et al.: Effect of pranlukast on bronchial inflammation in patients with asthma. Clin. Exp. Allergy(2000) 30:1008–1014.
   PubMed Web of Science ®Google Scholar
• NAKAMURA Y, HOSHINO M, SIM JJ, ISHII K, HOSAKA K, SAKAMOTO T: Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax (1998) 53:835–841.
   PubMed Web of Science ®Google Scholar
• BARNES NC, PUJET JC: Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax (1997) 52:523–527.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY TC, GEORGIOU P, HOWLAND K, DENNIS M, COMPTON CH, BARNES NC: Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers. Thorax (1997) 52:519–522.
   PubMed Web of Science ®Google Scholar
• GROSSMAN J, FAIFERMAN I, DUBB JW et al.: Results of the first US double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. I Asthma. (1997) 34:321–328.
   PubMed Web of Science ®Google Scholar
• YANAGAWA H, SUGITA A, AZUMA M et al.: Long-term follow-up of pulmonary function in bronchial asthma patients treated with pranlukast. Lung (2004) 182:51–58.
   PubMed Web of Science ®Google Scholar
• McGILL KA, BUSSE WW: Zileuton. Lancet (1996) 348:519–524.
   PubMed Web of Science ®Google Scholar
• Zileuton for asthma. Med. Lett. Drugs Tiler. (1997) 39(995):18–19.
   Google Scholar
• LAZARUS SC, LEE T, KEMP JP: Safetyand efficacy of zileuton in patients with chronic asthma. Am. Manag. Care. (1998) 4:841–848.
   PubMed Web of Science ®Google Scholar
• LU MC, DUBE LM, LANCASTER J: Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. I Allergy Clin. brimunol. (1996) 98:859–871.
   PubMed Web of Science ®Google Scholar
• KANE GC, POLLICE M, KIM JC et al: A controlled trial of the effect of the 5-lypoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. Allergy Gin. Immunol (1996) 97:646–654.
   PubMed Web of Science ®Google Scholar
• ISRAEL E, COHN J, DUBE L, DRAZEN JM: Effect of treatment with zileuton, a 5-lypoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. (1996) 275:931–936.
   Google Scholar
• BISGAARD H: Leukotriene modifiers in pediatric asthma management. Pediatrics (2001) 107:381–390.
   PubMed Web of Science ®Google Scholar
• •An importsant review about the use of leukotriene modifiers in paediatric asthma.
   Google Scholar
• VALACER DJ: New treatments for asthma: the role of leukotriene modifier agents. Natl. Med. Assoc. (1999) 91:26S–39S.
   Google Scholar
• HERMANSEN CL: Exercise-induced bronchospasm versus exercise-induced asthma. Am. Fam. Physician. (2004) 15:808.
   Google Scholar
• ZYFLO FIRMTAB (zileuton tablets): Physicians' Desk Reference (53rd Edition). Medical Economics Co, Montvale, MJ, USA (1999) 481–483.
   Google Scholar
• SAMPSON AP, CASTLING DP, GREEN CP, PRICE JF: Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch. Dis. Child. (1995) 73:221–225.
   PubMed Web of Science ®Google Scholar
• KIKAWA Y, MIYANOMAE T, INOUE Y et al.: Urinary leukotriene E4 after exercise challenge in children with asthma. I Allergy Clin. brimunol. (1992) 89:1111–1119.
   PubMed Web of Science ®Google Scholar
• DAHLEN B, ROQUET A, INMAN MD et al. : Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. Allergy Gin. brimunol. (2002) 109:789–793.
   PubMed Web of Science ®Google Scholar
• PERONI DG, PIACENTINI GL, PIETROBELLI A et al.: The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. Ear: Respir J. (2002) 20:104–107.
   PubMed Web of Science ®Google Scholar
• LENNEY W, WELLS NEJ, O'NEILL BA: The burden of paediatric asthma. Ear: Respir. Rev (1994) 4:49–53.
   Google Scholar
• LOFTUS BG, PRICE JF: Clinical and immunological characteristics of preschool asthma. Clin. Exp. Allergy (1986) 16:251–257.
   Web of Science ®Google Scholar
• STEINSHAMN S, SANDSUND M, SUE-CHU M, BJERMER L: Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Scand. I Med. Sci. Sports. (2002) 12:211–217.
   PubMed Web of Science ®Google Scholar
• BISGAARD H, LOLAND L, ANHOJ J: NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am. .1. Respir. Crit. Care. Med. (1999) 160:1227–1231.
   PubMed Web of Science ®Google Scholar
• BROOKS EG, HAYDEN ML: Exercise-induced asthma. Nurs. Gin. North. Am. (2003) 38:689–696.
   PubMed Web of Science ®Google Scholar
• RICCIONI G, DELLA VECCHIA R, MENNA V, LAMBO MS, DI ILIO C, D'ORAZIO N: The antileukotrienes in the therapy of bronchial asthma. Rec. Prog. Med. (2003) 94:509–515.
   PubMedGoogle Scholar
• STORMS WW: Review of exercise-induced asthma. Med. Sci. Sports. Exerc. (2003) 35:1464–1470.
   PubMed Web of Science ®Google Scholar
• •An important review about ETA and therapy with leukotriene modifiers.
   Google Scholar
• SHETH KK: Activity-induced asthma. Pediatr. Clin. North kn. (2003) 50:697–716.
   PubMed Web of Science ®Google Scholar
• KEMP JP, DOCKHORN RJ, SHAPIRO GG et al.: Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-14 year old children with asthma. Paediatrics (1998) 133:424–428.
   Web of Science ®Google Scholar
• VILLARAN C, O'NEILL SJ, HELBLING A et al.: Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Allergy Clin. brimunol. (1999) 104:547–553.
   Google Scholar
• ISRAEL E, FISCHER AR, ROSENBERG MA et al.: The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am. Rev. Respir. Dis. (1993) 148:1447–1451.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO H, NAGATA M, KURAMITSU K et at Inhibition of analgesic-induced asthma by leukotriene-receptor antagonist ONO-1078. Am. J. Respir. Crit. Care. Med. (1994) 150:254–257.
   PubMed Web of Science ®Google Scholar
• MICHELETTO C, TOGNELLA S, VISCONTI M, POMARI C, TREVISAN F, DAL NEGRO RW: Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study versus placebo. Allergy (2004) 59:289–294.
   PubMed Web of Science ®Google Scholar
• DAHLEN SE, MALMSTROM K, NIZANKOWSKA E et al.: Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am. I Respir. Crit. Care. Med. (2002) 165:9–14.
   PubMed Web of Science ®Google Scholar
• KEMP JP: Recent advances in the management of asthma using leukotriene modifiers. Am. I Respir. Med. (2003) 2:139–156.
   PubMedGoogle Scholar
• JENKINS C, COSTELLO J, HODGE L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. Br. Med. (2004) 328:434–435.
   PubMed Web of Science ®Google Scholar
• SZCZEKLIK A, SANAK M, NIZANKOWSKA-MOGILNICKA E, KIELBASA B: Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Carr. Opin. Palm. Med. (2004) 10:51–56.
   PubMed Web of Science ®Google Scholar
• MELTZER EO: Role of cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of 'one linked airway disease'. Ann. Allergy Asthma Immunol (2000) 84:176–185.
   PubMed Web of Science ®Google Scholar
• GROSSMAN J, RATNER PH, MATHEN R, ADEL GLASS J, DE JOUNG B: Pranlukast (ultair, 5B205312, 0N01078), an oral leukotriene receptor antagonist relieve symptoms in patients with seasonal allergic rhinitis. Allergy Immunol (1997) 99:S443.
   Google Scholar
• DONNELL AR, GLASS M, MINKWITZ MC, CASALE TM: The leukotriene D4 receptor antagonists, IC1204219, relief symptoms of acute seasonal allergic rhinitis. Am. I Respir. Crit. Care. Med. (1995) 151:1734–1739.
   PubMedGoogle Scholar
• NAYAK AS, PHILIP G, LU S, MALICE MP, REISS TF: Montelukast Fall
   Google Scholar
• •• Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann. Allergy Asthma. Immune]. (2002) 88:592–600.
   Google Scholar
• •An important randomised study comparing the efficacy and tolerability of MON versus loratadine in AR.
   Google Scholar
• PARNES SM: The role of leukotrienes inhibitors in patients with paranasal sinus syndrome. Carr. Opin. Otelaryngel. Neck. Surg. (2003) 11:184–191.
   PubMedGoogle Scholar
• STEINKE JVV, BRADLEY D, ARANGO P et al.: Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. I Allergy Clin. Immune]. (2003) 111:342–329.
   PubMed Web of Science ®Google Scholar
• BORISH L: The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann. Allergy Asthma Immune]. (2002) 88:16–22.
   PubMed Web of Science ®Google Scholar
• ARANGO P, KOUNTAKIS SE: Presence of cysteinyl leukotrienes in asthmatic patients with chronic sinusitis. Laryngoscope (2002) 112:1190–1192.
   PubMed Web of Science ®Google Scholar
• ARANGO P, BORISH L, FRIERSON HF JR, KOUNTAKIS SE: Cysteinyl leukotrienes in chronic hyperplastic rhinosinusitis. Otelaryngel Head. Neck. Surg. (2002) 127:512–515.
   PubMed Web of Science ®Google Scholar
• STEINKE JVV, CROUSE CD, BRADLEY D et al.: Characterization of interleukin-4-stimulated nasal polyp fibroblasts. Am. I Respir. Cell. Mol. Biol. (2004) 30:212–219.
   PubMed Web of Science ®Google Scholar
• HABERAL I, COREY JP: The role of leukotrienes in nasal allergy. Otelaryngel. Head Neck Surg. (2003) 129:274–279.
   PubMed Web of Science ®Google Scholar
• SCHUBERT MS: Allergic fungal sinusitis: pathogenesis and management strategies. Drugs (2004) 64:363–374.
   PubMed Web of Science ®Google Scholar
• SHEFTELL F, RAPOPORT A, WEEKS R, WALKER B, GAMMERMAN I, BASKIN S: Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache (2000) 40:158–163.
   PubMed Web of Science ®Google Scholar
• •A recent documented application of MON in migraine.
   Google Scholar
• ERBAGCI Z: The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. Allergy Clin. Immune]. (2002) 110:484–488.
   PubMed Web of Science ®Google Scholar
• REIMERS A, PICHLER C, HELBLING A, PICHLER WJ, YAWALKAR N: Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin. Exp. Allergy (2002) 32:1763–1768.
   PubMed Web of Science ®Google Scholar
• PACOR ML, DI LORENZO G, CORROCHER R: Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin. Exp. Allergy (2001) 31:1607–1614.
   Google Scholar
• BAGENSTOSE SE, LEVIN L, BERNSTEIN JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. Allergy Clin. Immune]. (2004) 113:134–140.
   Google Scholar
• RACKAL JM, VENDER RB: The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists. Skin Ther. Lett. (2004) 9:1–5.
   PubMedGoogle Scholar
• NETTIS E, PANNOFINO A, FANELLI M, FERRANNINI A, TURSI A: Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta. Derm. Venereel (2002) 82:297–298.
   PubMed Web of Science ®Google Scholar
• PEI AY, CHAN HH, LEUNG TF: Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr. Allergy Immune]. (2001) 12:154–158.
   PubMed Web of Science ®Google Scholar
• YANASE DJ, DAVID-BAJAR K: The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. Am. Acad. Dermatel. (2001) 44:89–93.
   PubMed Web of Science ®Google Scholar
• GUILPAIN P, VIALLARD JF, LAGARDE P et al.: Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (2002) 41:535–539.
   PubMed Web of Science ®Google Scholar
• VVECHSLER ME, PAUWELS R, DRAZEN JM: Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Sal (1999) 21:241–251.
   PubMed Web of Science ®Google Scholar
• NAYAK A: A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin. Pharmacother. (2004) 5:679–586.
   PubMed Web of Science ®Google Scholar
• ••Recent review about the effectiveness ofmontelukast on two important conditions of airways system: asthma and AR.
   Google Scholar